v3.24.1.u1
REVENUE RECOGNITION
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition REVENUE RECOGNITION
a.     Net revenues
The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows:
Three months ended March 31,Year ended December 31,
 20242023
2023
United States$90,543 $85,228 $349,743 
International markets:
Germany15,747 15,120 60,210 
Japan7,817 8,669 31,668 
Other international markets19,459 7,850 44,493 
International markets - Total43,023 31,639 136,371 
Greater China (1)4,937 5,315 23,224 
Total net revenues$138,503 $122,182 $509,338 
(1) For additional information, see Notes 12 and 13 to the Consolidated Financial Statements in the 2023 10-K.

The Company's net revenues by performance period are as follows:
Three months ended March 31,Year ended December 31,
 202420232023
Net revenues recognized in the reporting period from performance obligations satisfied in:
Reporting period$129,256 $117,338 $492,089 
Previous periods9,247 4,844 17,249 
Total net revenues$138,503 $122,182 $509,338 
b.     Contract balances
The following table provides information about trade receivables, unbilled receivables and contract liabilities from contracts with customers:
March 31,
2024		December 31,
2023
 UnauditedAudited
Trade receivables$60,401 $56,970 
Unbilled receivables$4,690 $4,251 
Deferred revenues (short-term contract liabilities)(15,870)(16,224)
During the three months ended March 31, 2024 and 2023 and the year ended December 31, 2023 the Company recognized $16,224, $18,028 and $18,028, respectively, which were included in the deferred revenues (short-term contract liability) balance at January 1, 2024 and 2023.